Ovarian Cancer Diagnostics Market: By Diagnosis Type (Biopsy, MRI scan, CT scan, PET Scan, Ultrasound, Blood Test, Others), By Disease Type (Stromal Tumour, Germ Cell Tumour, Epithelial Tumour, Primary Peritoneal Carcinoma), By End-User (Hospitals, Clinics, Diagnostic Centres, Others) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Ovarian Cancer Diagnostics Market size was valued at USD 2.6 billion in 2023 and is poised to grow at a CAGR of 8.8% from 2024-2030. Ovarian Cancer is an abnormal growth of cells that forms in the tissues of the ovary that further multiplies and invades and destroys healthy body tissues. The pelvic exam, imaging tests, blood tests, surgery, and other treatments are among those used for diagnosing ovarian cancer. The majority of cases of ovarian cancer occur in women between the ages of 55 and above. As the world's geriatric population rises and early detection and treatment are given more importance, it is getting more common, which is anticipated to hasten the development of the ovarian cancer diagnostic market. According to World Cancer Research Fund International, Ovarian cancer is the 8th most common cancer in women worldwide with about 313,000 new cases in 2020 thus its diagnosis becomes important and further increases the market. The increasing awareness about early cancer detection as well as changes in lifestyle choices like smoking, drinking, and obesity are currently driving the market. Moreover, the increase in the development of low-cost effective cancer diagnostic devices like CryoPop®, LumaGEM®, MarginProbe®, and picture archiving and communication systems (PACS) have opened up several opportunities for market growth.

Based on the procedure type, biopsy tests are most relevant and are used extensively. Liquid biopsy is the most used and accurate detection technique. For instance, in June 2023, LabCorp launched a new liquid biopsy to detect cancer-related biomarkers. Increasing R&D activities, rising healthcare expenditure, increasing health insurance coverages, and activities by non-governmental organizations (NGOs) also propel market growth. For instance, the “World Ovarian Cancer Coalition Atlas 2020” initiative was launched for raising awareness among the population. But the high cost of cancer diagnosis and treatment and insufficient knowledge and awareness among the female population of developing and under-developing countries hinder the growth of the market. Moreover, the lack of skilled professionals may hinder the detection and treatment of the patient and thus, may hamper the market growth. However, the initiatives taken by several governments, increasing healthcare spending, developing technology and instrumentation, increasing competition between key players, and developing infrastructure are expected to accelerate ovarian cancer diagnostic market development.

Ovarian Cancer Diagnostics Market Key Developments:
  • In April 2018, Boston Scientific acquired nVision Medical Corporation, a privately held company focused on women’s health. nVision developed the first and only device in the U.S. that cleared the FDA providing a platform for earlier diagnosis of ovarian cancer.
  • In December 2022, PredOmix launched a one-of-its-kind innovative cancer detection blood test, OncoVeryx-F, capable of detecting early-stage cancers in women with 98% accuracy.
  • In November 2021, U.S. Food and Drug Administration approved Cytalux (pafolacianine), an imaging drug intended to assist surgeons in identifying ovarian cancer lesions.

Global Ovarian Cancer Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Ovarian Cancer Diagnostics Market Dynamics

Increase in the ageing women population, rise in technological advancements for disease diagnosis, increase in the prevalence of ovarian cancer around the globe, and rise in healthcare awareness among key stakeholders are anticipated to bolster the ovarian cancer diagnostics market. Furthermore, highly developed healthcare infrastructure in developed countries, a rise in income per capita, and government initiative programs for increasing awareness about the ovarian cancer are expected to boost the ovarian cancer market growth over the forecast period. However, a high cost of the diagnostic procedure, lack of accuracy in disease diagnosis, stringent regulatory policies for diagnostic device approvals, and lack of early diagnostic tests and early warning systems might hamper the ovarian cancer diagnostics market over the forecast timeframe.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Ovarian Cancer Diagnostics Market Segmentation

By Diagnosis Type
  • Biopsy
  • MRI scan
  • CT scan
  • PET scan
  • Ultrasound
  • Blood test
  • Others
By Disease Type
  • Stromal tumour
  • Germ cell tumour
  • Epithelial tumour
  • Primary peritoneal carcinoma
By End User
  • Hospitals
  • Clinics
  • Diagnostic Centres
  • Others
By Geography
  • North America
  • Latin Americ
  • Europe
  • Asia Pacific
  • Middle East and Africa

Frequently Asked Questions

The ovarian cancer diagnostics market size was valued at USD 2.6 billion in 2023

The Lack of Awareness in Emerging and Low Income Economies

AstraZeneca Plc. (U.K.) Illumina, Inc. (U.S.) Bio-Rad Laboratories, Inc. (U.S.) Siemens AG (Germany) Roche Holding AG (Switzerland)

1. Executive Summary
2. Global Ovarian Cancer Diagnostics Market Introduction
2.1. Global Ovarian Cancer Diagnostics Market – Taxonomy
2.2. Global Ovarian Cancer Diagnostics Market – Definitions
2.2.1. By Diagnosis Type
2.2.2. By Cancer Type
2.2.3. By End User
2.2.4. By Region
3. Global Ovarian Cancer Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Ovarian Cancer Diagnostics Market Dynamic Factors - Impact Analysis
3.6. Global Ovarian Cancer Diagnostics Market – Competition Landscape
4. Global Ovarian Cancer Diagnostics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Ovarian Cancer Diagnostics Market, By Diagnosis Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
5.1. Imaging
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Blood Test
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Biopsy
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
6. Global Ovarian Cancer Diagnostics Market, By Cancer Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
6.1. Epithelial Tumor
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Germ cell Tumor
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Stromal  Cell Tumor
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
7. Global Ovarian Cancer Diagnostics Market, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
7.1. Hospital Laboratories
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Cancer Diagnostics Centers
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Research Institutions
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
7.4. Others
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.4.3. Market Opportunity Analysis
8. Global Ovarian Cancer Diagnostics Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Ovarian Cancer Diagnostics Market - Opportunity Analysis Index, By Diagnosis Type,By Cancer Type, End User, and Region, 2024 - 2030
9. North America Ovarian Cancer Diagnostics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
9.1. Diagnosis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Imaging
9.1.2. Blood Test
9.1.3. Biopsy
9.1.4. Others
9.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Epithelial Tumor
9.2.2. Germ Cell Tumor
9.2.3. Stromal Cell Tumor
9.2.4. Others
9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Laboratories
9.3.2. Cancer Diagnostic Centers
9.3.3. Research Institutes
9.3.4. Others
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Ovarian Cancer Diagnostics Market - Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2024 - 2030
9.6. North America Ovarian Cancer Diagnostics Market Dynamics – Trends
10. Europe Ovarian Cancer Diagnostics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
10.1. Diagnosis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Imaging
10.1.2. Blood Test
10.1.3. Biopsy
10.1.4. Others
10.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Epithelial Tumor
10.2.2. Germ Cell Tumor
10.2.3. Stromal Cell Tumor
10.2.4. Others
10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Laboratories
10.3.2. Cancer Diagnostic Centers
10.3.3. Research Institutes
10.3.4. Others
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Ovarian Cancer Diagnostics Market - Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2024 - 2030
10.6. Europe Ovarian Cancer Diagnostics Market Dynamics – Trends
11. Asia-Pacific Ovarian Cancer Diagnostics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
11.1. Diagnosis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Imaging
11.1.2. Blood Test
11.1.3. Biopsy
11.1.4. Others
11.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Epithelial Tumor
11.2.2. Germ Cell Tumor
11.2.3. Stromal Cell Tumor
11.2.4. Others
11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Laboratories
11.3.2. Cancer Diagnostic Centers
11.3.3. Research Institutes
11.3.4. Others
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Ovarian Cancer Diagnostics Market - Opportunity Analysis Index, By Diagnosis Type, By Cancer Type, End User, and Country, 2024 - 2030
11.6. Asia-Pacific Ovarian Cancer Diagnostics Market Dynamics – Trends
12. Latin America Ovarian Cancer Diagnostics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
12.1. Diagnosis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Imaging
12.1.2. Blood Test
12.1.3. Biopsy
12.1.4. Others
12.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Epithelial Tumor
12.2.2. Germ Cell Tumor
12.2.3. Stromal Cell Tumor
12.2.4. Others
12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Laboratories
12.3.2. Cancer Diagnostic Centers
12.3.3. Research Institutes
12.3.4. Others
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Ovarian Cancer Diagnostics Market - Opportunity Analysis Index, By Diagnosis Type, By Cancer Type,  End User, and Country, 2024 - 2030
12.6. Latin America Ovarian Cancer Diagnostics Market Dynamics – Trends
13. Middle East and Africa Ovarian Cancer Diagnostics Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
13.1. Diagnosis Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Imaging
13.1.2. Blood Test
13.1.3. Biopsy
13.1.4. Others
13.2. Cancer Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Epithelial Tumor
13.2.2. Germ Cell Tumor
13.2.3. Stromal Cell Tumor
13.2.4. Others
13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Laboratories
13.3.2. Cancer Diagnostic Centers
13.3.3. Research Institutes
13.3.4. Others
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Ovarian Cancer Diagnostics Market - Opportunity Analysis Index, By Diagnosis Type, By Cancer Type,  End User, and Country, 2024 - 2030
13.6. MEA Ovarian Cancer Diagnostics Market Dynamics – Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Diagnosis Type Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. F. Hoffmann-La Roche Ltd
14.2.2.  GlaxoSmithKline plc
14.2.3. Johnson & Johnson Services Inc
14.2.4. AstraZeneca plc
14.2.5.  Siemens Healthcare GmbH
14.2.6.  Quest Diagnostics Incorporated
14.2.7. Thermo Fisher Scientific
14.2.8.  Bio-Rad Technologies Inc.
14.2.9.  Abbott
15. Research Methodology
16. Key Assumptions and Acronyms
  • AstraZeneca Plc. (U.K.)
  • Illumina, Inc. (U.S.)
  • Bio-Rad Laboratories, Inc. (U.S.)
  • Siemens AG (Germany)
  • Roche Holding AG (Switzerland)
  • Myriad Genetics, Inc. (U.S.)
  • Epigenomics AG (Germany)
  • Thermo Fischer Scientific Inc. (U.S.)
  • VolitionRx Ltd. (Singapore)
  • Abcodia Ltd. (U.K.)

Adjacent Markets